Jaguar Health Inc (NAS:JAGX)
$ 1.13 -0.04 (-3.42%) Market Cap: 10.44 Mil Enterprise Value: 28.92 Mil PE Ratio: 0 PB Ratio: 0.52 GF Score: 35/100

Jaguar Health, Inc. - Special Call Transcript

Oct 20, 2020 / 07:00PM GMT
Release Date Price: $4045.95 (-2.38%)
Lisa A. Conte
Jaguar Health, Inc. - Founder, CEO, President & Director

Good afternoon. My name is Lisa Conte. I am the founder and CEO of Jaguar Health and our wholly owned subsidiary, Napo Pharmaceuticals, a company committed to novel plant-based prescription drug development. I want to begin by thanking all of you for taking part in our very first Diarrhea Dialogues event.

We've designed the educational event with the key goal of raising awareness among the investor community and global business development context regarding the need for supportive care for people related to chronic, lower gastrointestinal tract distress, specifically the debilitating diarrhea that often results from cancer and cancer therapy, also referred to as cancer therapy related diarrhea, or CTD.

Research shows CTD occurs in up to 80% of cancer patients and is far from a trivial problem. The condition not only has an enormous impact on cancer patients comfort and sensitivity, over 50% of the time diarrhea triggers the need for drug holidays, dose reductions or treatment failure during cancer therapy, which

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot